We are interested in the side effects of medications commonly used to treat diseases like chronic myelogenous leukemia. In particular, we are interested in the effects on blood vessel cells, white blood cells, and platelets. Our data will allow us to determine any effects that these medications have on human white blood cells and platelets.
This is a Phase 2b study to evaluate the safety, tolerability and preliminary efficacy of autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with GMG. The cell product will be referred to as "Descartes-08".
Patients with Chronic Kidney Disease(CKD) who receive medical care at Tufts Medicine will be invited to join a CKD research registry. The registry will record their medical information related to CKD and future researchers will be allowed to contact patients to ask if they would like to join a CKD related research study. There is nothing patients have to do once they join the registry, and joining a CKD research study is entirely optional.
Gore has developed and manufactures the GORE® SYNECOR Intraperitoneal Biomaterial device (GORE® SYNECOR IP Device) to offer clinicians a mesh material intended for the repair of ventral/incisional hernias that may require the addition of a nonabsorbable reinforcing or bridging material. The primary study objective is to assess SYNECOR Biomaterial performance on incisional hernia patients over an extended amount of time through multiple methods. The secondary study objective is to conduct configuration-specific assessments to address areas of medical interest.
In this study, researchers are hoping to improve post-operative pain control and reduce opioid use using a technique called TAP block. A TAP block is a form of pain relief that "blocks" the pain receptors in a person's abdomen and can be performed during minimally invasive hysterectomy. Enrolled participants undergoing minimally invasive hysterectomy will be randomized to three pain control or TAP block options.
Percutaneous Coronary Intervention (PCI) involves positioning of a stent under Xray guidance to treat coronary arterial stenosis. It then requires intraprocedural assessment of stent positioning and deployment. Standard assessment is done using 2-dimensional angiography possibly augmented with stent enhancement algorithms (e.g. StentViz, GE HealthCare) and/or Intravascular Imaging such IVUS. IVUS brings excellent visualization and clinical information, but it is limited by catheter cost, workflow and time.
This is a multi-center first-in-human, Phase 1, open-label, dose ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of single ascending doses of SBT777101 administered intravenously (IV) in subjects with active rheumatoid arthritis (RA) and an inadequate response to at least 2 prior biologic or targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD) therapies with different mechanisms of action.
To confirm the longer-term safety and effectiveness of the LVIS Device. The aim of this study is to collect and provide FDA with longer term clinical performance of the LVIS device.
This clinical research study to look at the effectiveness and safety of an investigational vaccine that is being developed by Janssen Pharmaceuticals. This study is looking at whether the investigational vaccine can help prevent a bloodstream infection caused by E. coli bacteria, which is commonly found in the gastrointestinal tract, and can spread to the urinary tract and blood stream.
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with IPF with or without standard-of-care. Patients meeting the eligibility criteria for the study will be randomized with a 2:1 ratio to DWN12088 150 mg BID or the matching placebo. Randomization will be stratified according to other medications for IPF (patients receiving pirfenidone or nintedanib and patients with no treatment for IPF, with a minimum of 30% of patients on no treatment) and to country (patients in United States or South Korea).
This is a Phase 2 open-label, multicenter study to evaluate the clinical activity, safety, pharmacokinetics (PK), and biomarker profile of ZN-c3 in subjects with locally advanced or metastatic solid tumor malignancies harboring biomarkers related to deoxyribonucleic acid (DNA) damage pathways.
REACT-AF is a multicenter, prospective, randomized clinical trial comparing two treatment strategies for stroke prevention in patients with a history of paroxsymal or persistent atrial fibrillation and moderate stroke-risk.
The purpose of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation Device (“Vanquish”) in subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer
To assess the safety and efficacy of oral medication, deucravacitinib (DEUC) at 3 mg twice daily (BID) vs. 6 mg BID vs. the placebo in participants with active Sjögren’s syndrome (SjS).
